You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 474 Intratumoral CTLA-4-targeting INTASYL™ self-delivering RNAi enhances tumor control in combination with systemic anti-PD-1 antibody therapy in vivo suggesting a strategy to mitigate irSAEs

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Checkpoint Blockade Therapy
474 Intratumoral CTLA-4-targeting INTASYL™ self-delivering RNAi enhances tumor control in combination with systemic anti-PD-1 antibody therapy in vivo suggesting a strategy to mitigate irSAEs

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 202312607
Dec 202323010
Jan 20242000
Feb 20241605
Mar 20242601
Apr 20241803
May 20242602
Jun 20241802
Jul 20241406
Aug 2024603
Sep 20241602
Oct 20241602
Nov 20241005
Dec 2024805
Jan 20251006
Feb 2025004
Mar 2025004
Apr 2025003
May 2025004
Jun 2025003
Total353077